IP
IndiaPulse

ECOSMOBLTY

Small Cap

Ecos (India) Mobility & Hospitality Limited

Auto

Ecos (India) Mobility & Hospitality Limited operates in EV Components, within the Auto sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹126.14
+0.70 · +0.56%
Quote09 Jun, 10:02 am
Fundamentals08 Jun 2026 · screener
Score08 Jun, 11:00 pm · v4.2-nightly
Tags02 May 2026
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Strong fundamentals, management trust is supportive, price trend is neutral, and recent execution is mixed.

Suggested next step
Candidate for deeper work
Valuation is strong. Wait for stronger Trust evidence before treating this as high conviction.
U-Score
DEEP VALUE
79

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Healthy Trust
84

low confidence · 0/0 claims checked

Technical
Neutral
45

Timing lens: price trend and sector relative strength.

Result consistency
mixed
61

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 31 Mar 2026

Bad · 0/100

PAT -11% YoY · margin compression · Rev +17% YoY

Filed 31 Mar 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹207 Cr+16.9%+0.5%
EBITDA₹24 Cr-7.7%+4.3%
Operating margin12.0%-300 bps+100 bps
PAT₹16 Cr-11.1%+14.3%
PAT margin7.7%-244 bps+93 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business and thesis

Issuer presentation review pending

Ecos (India) Mobility & Hospitality Limited operates in EV Components, within the Auto sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Technical timing lens

Trend score and candlestick chart

45Neutral

SMA20 -26.5% / mo · near 52W low

Stock trend: 41
Sector RS: 52
Sector 3M: +0.4% vs Nifty +0.1%

Technical chart

ECOSMOBLTYweekly · 3Y-69.3%
Latest close ₹126.14 on 2026-06-09
Bar
+1.7%
RSI
38
MACD hist
2.66
52W pos
9%
Hover for OHLC, volume, and indicators. Use range buttons above the chart to zoom.
₹88₹175₹261₹348₹43552H52L2024-122025-032025-062025-092025-122026-03Vol2024-112025-042025-102026-032026-06
Up bar
Down bar
Volume
Result date
SMA 50
RSI(14)

Technical trend read

Neutral

Trend is undirectional — long-term trend unclear. RSI 38.

  • SMA20 falling (~36.0% over last month) — short-term momentum negative.
  • RSI(14) at 38 — sideways, no extreme reading.
  • MACD above signal but histogram contracting — bullish momentum cooling.
  • 63% off 52W high · 21% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Deep research

Valuation, score drivers, trust methodology, financials, and peers

Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.

79U-SCORE
Top Setup

Fundamental score breakdown

DEEP VALUE
Valuation18/30
Growth22/25
Quality14/20
Balance Sheet13/15
Cash Flow6/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
79

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

79/100 · DEEP VALUE

Positive drivers

  • Piotroski is strong at 8/9.
  • Fair-value margin of safety is positive at 60.2%.
  • Growth contributes 22/25 to the score.

Main drags

  • Valuation is weaker at 18/30; verify the latest quarterly trend.
  • Cash flow is weaker at 6/10; verify the latest quarterly trend.
  • Quality is weaker at 14/20; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
13.1
PB
2.8
EV/EBITDA
6.3
ROE
23.7%
ROCE
30.3%
FCF Yield
2.9%
Debt/Equity
0.0
MoS
+60.2%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 08 Jun 2026
v4.2-nightly
Final score
79
Previous: 79
Verdict
DEEP VALUE
Previous: DEEP VALUE
Margin of safety
+60.2%
Previous: +60.5%

Score history

12 stored score snapshots. Latest stored move: +0 points.

08 Jun 2026
v4.2-nightly
78
77
81
81
83
86
82
79
79
79
79
79

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Trust Score
84Healthy Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Healthy Trust: Claim history is still being built. It ranks around the 97th percentile of the scored universe and 93rd percentile within Auto. No major sub-score weakness stands out.

High Trust Lite: Promoter holding is 67.8%. Key concern: ROCE trend is -7.7%.

Computed 22 May 2026
trust-lite-v1
0 docs indexed · 0 concall links
Score band
Healthy Trust

Generally investable credibility. Look for weak sub-scores before increasing position size.

Relative rank
97th percentile

overall median 67 · Auto: 93rd pctile, median 71 · Small: 99th pctile, median 65

Evidence depth
Financial-only

0 documents indexed, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Healthy Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
89
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
80
strong · capital discipline
Results
61
acceptable · quarterly consistency

Trust positives

  • Promoter holding is 67.8%.
  • Promoter pledge is zero.
  • FCF yield is 7.2%.
  • 5 years of positive FCF.

Trust risks

  • ROCE trend is -7.7%.
  • 1/7 recent quarters had positive YoY PAT growth.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Intrinsic value

Graham Number
₹97.71
-29.1% MoS
DCF Fair PE
33.0
DCF Fair Value
₹316.8
+60.2% MoS
PEG
0.15

Fundamentals

Valuation

P/E
13.10
P/B
2.83
EV/EBITDA
6.27
Market Cap
757.00Cr

Profitability

ROE
23.70%
ROCE
30.30%
ROA
14.04%
Dividend Y
1.91%

Growth (CAGR)

Revenue 5Y
51.00%
EPS 5Y
136.00%
Revenue 3Y
25.00%
EPS 3Y
12.00%

Balance Sheet

Debt/Equity
0.03
Interest Coverage
94.00×
Altman Z
6.87
Book Value
44.20

Cash Flow

FCF Yield
2.91%
FCF Positive Y
6/5
OCF
68.00 Cr
EPS TTM
9.60

Shareholding

Promoter Hold
67.79%
Promoter Pledge
0.00%
Momentum 52W
8%

Financial History

Updated 9/6/2026

Revenue

₹ Cr
Latest: 148-64.4% vs prev
0792.4Mar 2026: 792Mar 2025: 636Mar 2024: 548Mar 2023: 416Mar 2022: 148FY26FY25FY24FY23FY22

Net Profit

₹ Cr
No data

Return on Equity

%
No data
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.